Canada’s leading marijuana producer Canopy Growth said shareholders approved its deal to acquire the American cannabis chain Acreage Holdings — if the U.S. legalizes marijuana federally.
Canada’s leading marijuana producer Canopy Growth said shareholders approved its deal to acquire the American cannabis chain Acreage Holdings — if the U.S. legalizes marijuana federally.
Canada’s leading pot producer Canopy Growth said Wednesday that shareholders approved its deal to acquire the American cannabis chain Acreage Holdings.
CALGARY , June 17, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale...
More American farmers are turning to hemp amid the low price of grain and the prolonged trade war between the United States and China. Yahoo Finance's Zack Guzman, Sibile Marcellus, and Heidi Chung...
Left and right, Seaport Global is rolling back prices -- or at least price targets -- on Canadian cannabis stocks. (It's kind of like a sale at Wal-Mart, but in a bad way). On Wednesday we looked at...
High Tide Announces AGCO Authorization to Open Canna Cabana Toronto Retail Cannabis Store
There are two likely reasons PAX picked these four specific marijuana stocks.
Aphria stock was flying high Friday morning after the marijuana firm announced it was among four Canadian growers to partner with San Francisco-based PAX Labs for cannabis vaporizers.
San Francisco-based Pax Labs , which makes app-controlled vaporization technologies and devices for cannabis flowers and concentrates, announced Friday agreements with leading cannabis companies to leverage...
TORONTO , June 7, 2019 /CNW/ - PAX Labs, Inc., a leading consumer technology brand in cannabis, is pleased to announce that Aphria Inc. ("Aphria") (APHA.TO)(APHA), Aurora Cannabis Inc. ("Aurora") (ACB.TO)(ACB),...
Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit.
Grown in greenhouses, Aphria offers premium medical grade cannabis. Located in Leamington, Ontario, in Southwestern Ontario, the heart of the greenhouse-producing sector for plant and produce, Aphria is built from a lengthy background of greenhouse growing and business experience.
The purpose of Aphria’s Facebook page is to engage with patients, clients, health care professionals and the community through sharing and discussing Aphria products and services, industry insiders and government updates. Please review our community guidelines designed to help provide an inclusive environment for all of Aphria’s communities.
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.
Corporate GovernanceAphria Inc.’s ISS Governance QualityScore as of January 28, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 6; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.For Patients
At Aphria, we understand that every patient’s situation is unique, which is why we provide a personalized level of care to suit the individual needs of each patient. Our patient care does not stop with the initial consultation. Our team is committed to providing guidance and continued support throughout the entire patient experience.
For Health Professionals
Government and regulatory bodies set the baseline standards for medicines like medical cannabis. These standards are generally the minimum requirements necessary to ensure an adequate product. Aphria believes adequate is not good enough. Consistency, safety, and
efficacy are our priority.
For Investors
We are committed to providing pharma-grade medical cannabis and superior patient care, while balancing patient economics and returns to shareholders.